SCHEMBL19967277

SCHEMBL19967277

O=S1(=O)c2ccc(OC3CCC3)cc2CN1Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.44
▸ MAPT P10636 1/20 0.43
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ROCK1 Q13464 5/20 0.41
▸ ROCK2 O75116 3/20 0.41
▸ CCR2 P41597 2/20 0.41
▸ OPRK1 P41145 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ MDM2 Q00987 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ ACACB O00763 2/20 0.38
▸ HRH3 Q9Y5N1 2/20 0.38
▸ HRH1 P35367 1/20 0.38
▸ ATM Q13315 1/20 0.37
▸ FAAH O00519 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19967337 0.85 TDP1 (0.42) TDP1MAPTGAASMN1; SMN2ROCK1
SCHEMBL19967340 0.82 FFAR1 (0.49) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL19967065 0.80 FFAR4 (0.50) SMN1; SMN2HRH3
SCHEMBL19967185 0.79 TDP1 (0.46) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL19967098 0.78 TDP1 (0.45) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL21168479 0.77 TDP1 (0.46) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL19967336 0.75 TDP1 (0.52) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL19967190 0.75 TDP1 (0.52) TDP1MAPTMDM2KMT2ACTDSP1
SCHEMBL19967156 0.74 FFAR4 (0.49) TDP1MAPTGAASMN1; SMN2HRH3
SCHEMBL16116928 0.72 TDP1 (0.58) TDP1MAPTMDM2KMT2ACTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3509588-B1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS INTEGRAL HEALTH INC (US) 2023-06-07 — — EP disclosed
US-20210347768-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS VALO HEALTH, INC. 2021-11-11 — — US disclosed
US-10865201-B2 Bicyclic compounds useful as GPR120 modulators VALO HEALTH, INC. (US) 2020-12-15 — — US disclosed
US-20190218208-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS VALO HEALTH, INC. 2019-07-18 — — US disclosed
WO-2018049328-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS NUMERATE, INC. (US) 2018-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10865201-B2 Bicyclic compounds useful as GPR120 modulators GPR119, GPR180, GPR65 TDP1 4753/4885MAPT 3630/4885GAA 2227/4885
US-20190218208-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 TDP1 4753/4885MAPT 3630/4885GAA 2227/4885
US-20210347768-A1 BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS GPR119, GPR180, GPR65 TDP1 4753/4885MAPT 3630/4885GAA 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback